Purchase of an Echo 650 acoustic liquid handler with Access workstation

项目摘要 请求提供支助，以购买配备Access工作站的Echo 650声学液体处理器 以取代Janus NanoHead，现有的和老化的低容量液体处理器于2008年购买， 分子筛选和蛋白质表达设施在费城的Wistar研究所。本文书 升级对于该机制继续提供最先进的支持， 药物发现所需的高通量生物化学和基于细胞的测定。事实上，威斯塔已经做出了 通过招募其第一位药物化学家Joseph M.萨尔维诺，谁是 本申请的主要研究者。萨尔维诺博士和其他九个主要和次要用户谁持有 联合17个独特的NIH补助金（R01/R35/R61/P01/UM1/U54/DP2）要求Echo 650与Access 工作站开发改进的生物化学和基于细胞的测定，产生更好的数据， 关于新型结构-活性关系的更明智的决策。目前还没有类似的 Wistar研究者可以使用的仪器。 Echo 650是一款高精度、低容量、非接触式液体处理器， 将大量液体从一个微孔板转移到另一个微孔板。采用直接稀释法， 与传统的连续稀释相比，小分子的效力具有更好的精确度。小型化 这样的分析也降低了研究成本。Access工作站是集成了 Echo 650允许高通量筛选所需的自动化板处理和命中挑选， 活性化合物由于源极板之间没有接触，因此该技术消除了化合物 防止残留并保护储存板中现有化合物的完整性。初步数据显示， 在此应用中，证明Echo 650是一种优于我们现有Janus Nanohead的上级技术。在 此外，我们还表明，我们有必要的基础设施，使我们的分析，以1536孔格式。 该仪器将显著提升我们在分析小型化方面的能力，同时 提高我们的数据质量。 该单位将被安置在分子筛选和蛋白质表达设施，由博士监督。 萨尔维诺，由乔尔·卡塞尔先生管理。萨尔维诺博士和卡塞尔先生总共有40多年 制药行业的经验。该设施是很好的考虑和累积排名与得分 在2018年NIH/NCI癌症中心支持补助金（CCSG）审查中获得“卓越”。我们正在寻求 将我们现有的低容量液体处理技术升级为上级最先进的非接触式纳升 带Access工作站的Echo 650中的液体处理技术，以最佳方式支持学术 Wistar研究所的药物发现计划。

PROJECT SUMMARY Support is requested for the purchase of an Echo 650 acoustic liquid handler with Access workstation to replace the Janus NanoHead, the existing and aging low volume liquid handler purchased in 2008 within the Molecular Screening and Protein Expression Facility at The Wistar Institute in Philadelphia. This instrument upgrade is critical for the Facility to continue to provide state-of-the-art support for the development of robust, high-throughput biochemical and cell-based assays required for drug discovery. Indeed, Wistar has made a commitment to academic drug discovery by recruiting its first medicinal chemist, Dr. Joseph M. Salvino, who is the Principal Investigator of this application. Dr. Salvino and nine other major and minor users who hold a combined 17 unique NIH grants (R01/R35/R61/P01/UM1/U54/DP2) have requested the Echo 650 with Access workstation to develop improved biochemical and cell-based assays that generate better data which will enable more informed decision making regarding novel structure-activity relationships. There are currently no similar instruments that are accessible to Wistar investigators. The Echo 650 is a highly accurate, low volume, non-contact liquid handler that moves nanoliter volumes of liquid from one microplate to another using sound waves. Using direct dilution, it can determine the potencies of small molecules with better precision as opposed to traditional serial dilution. The miniaturization of such assays also reduces research costs. The Access workstation is the stacker unit integrated with the Echo 650 which allows for automated plate handling necessary for high-throughput screening and hit picking of active compounds. Because there is no contact between source plates, this technology eliminates compound carry-over and protects the integrity of existing compounds in storage plates. The preliminary data described in this application demonstrate that the Echo 650 is a superior technology to our existing Janus Nanohead. In addition, we also show that we have the necessary infrastructure to miniaturize our assays to 1536-well format. This instrument will significantly upgrade our capabilities regarding assay miniaturization while simultaneously increasing the quality of our data. The unit will be housed in the Molecular Screening and Protein Expression Facility, overseen by Dr. Salvino and managed by Mr. Joel Cassel. Both Dr. Salvino and Mr. Cassel have over 40 years aggregate experience in the pharmaceutical industry. The facility is well regarded and cumulatively ranked with a score of “Exceptional” at the 2018 NIH/NCI Cancer Center support Grant (CCSG) review. We are seeking to upgrade our existing low volume liquid handling technology to a superior state of the art, non-contact nanoliter liquid handling technology in the Echo 650 with Access workstation in order to optimally support the academic drug discovery initiatives of The Wistar Institute.